How independent specialist review helped other patients

Clinical background

Following breast-conserving surgery and sentinel lymph node biopsy, the histology reported a 1.6 cm grade 2 invasive ductal carcinoma, ER 8/8, PR 6/8, HER2 immunohistochemistry 1+, Ki-67 18%, margins clear, 0/3 sentinel nodes involved. The patient had been offered adjuvant chemotherapy followed by five years of an aromatase inhibitor and wanted to understand the reasoning before deciding.

The patient's question

“Does the pathology in this case indicate a genomic recurrence-risk assay, and how is the absolute benefit of adjuvant chemotherapy usually estimated alongside endocrine therapy?”

How the review was carried out

1. 1Structured extraction of the operative note, histopathology report, staging imaging and clinic letters into a single chronological case summary.
2. 2AI-assisted consistency check comparing the recorded TNM stage, receptor status and Ki-67 against the narrative in the multidisciplinary team note.
3. 3Independent review by a consultant medical oncologist in active breast practice, with no affiliation to the treating hospital.

What the report set out

• The recorded stage and biomarker profile were internally consistent across the pathology report and MDT note.
• The reviewer noted that node-negative, ER-positive, HER2-negative disease is the group in which international guidelines most often discuss a genomic recurrence-risk assay to inform, not replace, the chemotherapy conversation.
• The report set out how absolute benefit is normally expressed — the difference in estimated recurrence risk with and without chemotherapy — and which patient-specific factors, including menopausal status and comorbidity, modify that estimate.

Clinical background

The patient had hypertension, type 2 diabetes and a family history of premature coronary disease. A CT coronary angiogram reported mild non-calcified plaque with less than 50% stenosis; invasive angiography confirmed non-obstructive epicardial disease. Symptoms persisted on a beta blocker and statin.

The patient's question

“What clinical entities are usually considered when angina persists despite non-obstructive coronary arteries, and what further assessment is typically discussed?”

How the review was carried out

1. 1Timeline reconstruction across two hospitals, aligning symptom diary entries with investigation dates and medication changes.
2. 2Radiology and angiography report review by a consultant cardiologist with a chest-pain clinic practice.
3. 3Cross-check of documented risk factors and lipid results against the recorded secondary-prevention plan.

What the report set out

• The reviewer explained that non-obstructive coronary arteries do not exclude ischaemia, and that coronary microvascular dysfunction and vasospastic angina are the entities usually considered in this pattern.
• The report described the investigations commonly discussed in this setting, including invasive coronary function testing and stress perfusion imaging, and noted their availability varies by centre.
• Documented LDL-cholesterol remained above the target range usually applied to patients with diabetes and established plaque — flagged as a point to raise with the treating team.

Clinical background

Seizures began at age 5, with two anti-seizure medicines tried at adequate doses without sustained control. EEG showed a left temporal focus. A 1.5T MRI was reported as showing no structural abnormality.

The patient's question

“Has the imaging been acquired and reported using a protocol suited to identifying subtle epileptogenic lesions in a child with a defined electrographic focus?”

How the review was carried out

1. 1Review of DICOM images alongside the EEG report by a paediatric neurologist and a neuroradiologist.
2. 2Comparison of the acquisition parameters with published epilepsy-protocol recommendations.
3. 3Plain-language explanation prepared for the family with a separate technical section for the treating team.

What the report set out

• The scan was a standard brain protocol rather than a dedicated epilepsy protocol; thin-slice coronal sequences angled to the hippocampus were not included.
• The reviewers noted that subtle focal cortical dysplasia is a recognised cause of drug-resistant focal epilepsy that can be missed without a targeted protocol and 3T imaging where available.
• The report emphasised that a normal MRI does not rule out a surgically treatable lesion and that referral pathways to a specialist epilepsy service exist in the child's own health system.

Clinical background

Records covered three hospitals over five years: two colonoscopies with biopsies, intermittently raised faecal calprotectin, a normal MR enterography, and several courses of empirical treatment. No consolidated summary existed.

The patient's question

“What has objectively been demonstrated across the available investigations, and which gaps remain in the diagnostic record?”

How the review was carried out

1. 1Consolidation of 148 pages of correspondence, endoscopy and histology reports into one indexed clinical timeline.
2. 2Review by a consultant gastroenterologist with an inflammatory bowel disease practice.
3. 3Explicit separation of objective findings from provisional labels used in correspondence.

What the report set out

• Histology from both colonoscopies had reported no granulomas or chronic architectural change; the Crohn's label originated from a single clinic letter rather than a tissue diagnosis.
• Two faecal calprotectin values were raised but had not been repeated after treatment, so their significance was unresolved in the record.
• The reviewer listed the objective criteria usually required before a diagnosis of inflammatory bowel disease is recorded, and noted which had and had not been met.